Synvista Therapeutics Increases Commercial Focus by Appointing David C. Tantillo Senior Director of Marketing...(m 2006 to 2007 he was U.S.Marketing Dire...)

Date:5/12/2008

m 2006 to 2007, he was U.S. Marketing Director at Mayne Pharma, which was acquired by Hospira. Prior to that, from 2004 to 2005 he was President of Pinnacle Healthcare Marketing, an independent consultancy to the healthcare industry. Mr. Tantillo also has held a variety of marketing and brand management positions at Becton Dickinson, F. Hoffmann- LaRoche, Schering AG (Berlex Laboratories), Eli Lilly and Company (PCS Health Systems) and Baxter Healthcare (Caremark International).

Mr. Tantillo received MPH and MBA degrees from Illinois Benedictine College, and a BS in Mechanical Engineering from Iowa State University.

About Haptoglobin

The polymorphic haptoglobin (Hp) protein is derived from two alleles, 1 and 2, existing at the Hp genetic locus. Three phenotypes linked to the three genotypes, Hp 1-1, Hp 1-2 and Hp 2-2, can be identified using a proprietary ELISA assay being developed by Synvista. In multiple independent prospective longitudinal studies of more than 20,000 individuals, it has been established that the Haptoglobin genotype is an independent risk factor for cardiovascular disease, with a specific relationship to patients with diabetes mellitus. After accounting for conventional cardiovascular risk factors and diabetes characteristics in these studies, research has demonstrated that there is a 2- 5 fold increased risk of cardiovascular disease in people with both diabetes and the Hp 2-2 genotype (approximately 40 percent of all diabetes patients).

Currently, Synvista is developing a proprietary diagnostic test to determine haptoglobin genotype in order to identify the subset of diabetics at greatest risk for cardiovascular disease. Since this test is designed to determine which diabetic patients display the highest levels of oxidative stress (Hp 2-2 individuals), it can also be used to identify the subset of diabetics who may benefit most from potent anti-oxidizing agents, such as SYI- 2074 (previously ALT-2074). The test also
'/>"/>

SOURCE Synvista Therapeutics, Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related biology technology :

1. Synvista Therapeutics Highlights Newly Published Data Demonstrating the Value of Haptoglobin Genotype Testing In People with Diabetes
2. Synvista Therapeutics to Present at the 10th Annual BIO CEO & Investor Conference
3. Synvista Therapeutics to Develop Topical Formulation of ALT-2074 for the Treatment of Psoriasis
4. Synvista Therapeutics to be Featured on Wallst.net
5. Synvista Therapeutics to Present at the BIO InvestorForum 2007
6. President and CEO of Velcura Therapeutics Inc. Named the 2008 Grant Thornton Leader and Innovator of the Year
7. NuVasive Signs Definitive Agreement to Acquire Osteocel Biologics Business from Osiris Therapeutics
8. Halozyme Therapeutics Reports 2008 First Quarter Financial Results
9. Innovative and Forward-Thinking Experts to Deliver Keynote Presentations at IBCs 13th Annual Drug Discovery & Development of Innovative Therapeutics World Congress
10. ImaRx Therapeutics Signs Letter of Intent With Microbix Biosystems for the Sale of Urokinase
11. Lorus Therapeutics Strengthens Its Senior Management Team Through Internal Promotions